A study of Platelet INhibition using a 'POINT of care' platelet function test, following Primary Percutaneous Coronary Intervention for ST ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2011-2012

ABSTRACT

Background and study aims An ST segment Elevation Myocardial Infarction (STEMI) is a heart attack caused by a completely blocked blood vessel. Heart attacks are increasingly being treated by re-opening the blocked heart artery and placing a metal-mesh tube (stent). This is called primary percutaneous coronary intervention or PPCI. In addition to scaffolding the artery with a stent, drugs are used to thin the patient’s blood. We have recently changed the drugs given to patients presenting to the Bristol Heart Institute with heart attacks. The drugs we have selected are potent blood thinners and have been shown to act very fast. We will describe the relationship between blood thinning at the end of the procedure with the time given for the drug to take effect, and ultimately with side effects developed within the first 30 days after stenting. Who can participate? Patients aged 18 and over with an acute STEMI (heart attack) and undergoing PPCI. What does the study involve? The patients’ blood clotting ability is assessed on arrival at the hospital, at the completion of the PPCI, and at 1, 2 and 24 hours after the completion of the PPCI. This is a simple blood test, taking 3 ml of blood at each time, a total of 15 ml of blood. Following the procedure, patients are usually transferred to the coronary care unit (CCU), where they receive further drug treatment, undergo an echocardiogram (heart scan), and contact is made with the cardiac rehabilitation team. Ideally, patients transfer from the CCU to a cardiology ward after 24 hours and discharge is arranged from 48 hours onwards. All patients are invited to a clinic 1 month later. At this appointment any ongoing symptoms/problems are assessed, a 12-lead ECG is undertaken (recording the heart's electrical activity), and a clinical examination is performed, including weight, height, heart rate and blood pressure. Where necessary, the patients' medication is adjusted and further investigations are arranged for ongoing care. What are the possible benefits and risks of participating? This is an observational study so there are no benefits or risks of participating. Where is the study run from? Bristol Heart Institute at the Bristol Royal Infirmary (UK). When is the study starting and how long is it expected to run for? March 2011 to October 2012. Who is funding the study? The study is funded from Above and Beyond Project 353. Who is the main contact? Dr Thomas Johnson Tom.Johnson@UHBristol.nhs.uk More... »

URL

http://www.isrctn.com/ISRCTN82257414

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Background and study aims \nAn ST segment Elevation Myocardial Infarction (STEMI) is a heart attack caused by a completely blocked blood vessel. Heart attacks are increasingly being treated by re-opening the blocked heart artery and placing a metal-mesh tube (stent). This is called primary percutaneous coronary intervention or PPCI. In addition to scaffolding the artery with a stent, drugs are used to thin the patient\u2019s blood. We have recently changed the drugs given to patients presenting to the Bristol Heart Institute with heart attacks. The drugs we have selected are potent blood thinners and have been shown to act very fast. We will describe the relationship between blood thinning at the end of the procedure with the time given for the drug to take effect, and ultimately with side effects developed within the first 30 days after stenting. \n\nWho can participate? \nPatients aged 18 and over with an acute STEMI (heart attack) and undergoing PPCI.  \n\nWhat does the study involve? \nThe patients\u2019 blood clotting ability is assessed on arrival at the hospital, at the completion of the PPCI, and at 1, 2 and 24 hours after the completion of the PPCI. This is a simple blood test, taking 3 ml of blood at each time, a total of 15 ml of blood. Following the procedure, patients are usually transferred to the coronary care unit (CCU), where they receive further drug treatment, undergo an echocardiogram (heart scan), and contact is made with the cardiac rehabilitation team. Ideally, patients transfer from the CCU to a cardiology ward after 24 hours and discharge is arranged from 48 hours onwards. All patients are invited to a clinic 1 month later. At this appointment any ongoing symptoms/problems are assessed, a 12-lead ECG is undertaken (recording the heart's electrical activity), and a clinical examination is performed, including weight, height, heart rate and blood pressure. Where necessary, the patients' medication is adjusted and further investigations are arranged for ongoing care.\n\nWhat are the possible benefits and risks of participating? \nThis is an observational study so there are no benefits or risks of participating.\n\nWhere is the study run from? \nBristol Heart Institute at the Bristol Royal Infirmary (UK).\n\nWhen is the study starting and how long is it expected to run for? \nMarch 2011 to October 2012. \n\nWho is funding the study? \nThe study is funded from Above and Beyond Project 353.  \n\nWho is the main contact? \nDr Thomas Johnson\nTom.Johnson@UHBristol.nhs.uk", 
    "endDate": "2012-10-31T00:00:00Z", 
    "id": "sg:clinicaltrial.ISRCTN82257414", 
    "keywords": [
      "drug treatment", 
      "coronary care unit", 
      "Main", 
      "patient", 
      "benefit", 
      "possible benefit", 
      "echocardiogram", 
      "clinic", 
      "cardiology", 
      "drug", 
      "heart rate", 
      "blood", 
      "Institute", 
      "platelet inhibition", 
      "stent", 
      "blood vessel", 
      "ongoing care", 
      "heart attack", 
      "March", 
      "heart", 
      "electrical activity", 
      "Lead", 
      "heart artery", 
      "clinical examination", 
      "method", 
      "patient blood", 
      "stenting", 
      "onwards", 
      "completion", 
      "simple blood", 
      "observational study", 
      "cardiac rehabilitation", 
      "artery", 
      "blood thinner", 
      "blood pressure", 
      "medication", 
      "transfer", 
      "October", 
      "metal", 
      "platelet function", 
      "run", 
      "myocardial infarction", 
      "recording", 
      "height", 
      "percutaneous coronary intervention", 
      "side effect", 
      "Johnson", 
      "hospital", 
      "weight", 
      "risk", 
      "discharge", 
      "UK", 
      "Appointment and Schedule"
    ], 
    "name": "A study of Platelet INhibition using a 'POINT of care' platelet function test, following Primary Percutaneous Coronary Intervention for ST elevation myocardial infarction (PINPOINT-PPCI)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/ISRCTN82257414"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/isrctn_ct_data_00001.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.423000.5", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410421.2", 
        "type": "Organization"
      }
    ], 
    "startDate": "2011-03-17T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1471-2261-14-44", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018754243", 
          "https://doi.org/10.1186/1471-2261-14-44"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "http://www.isrctn.com/ISRCTN82257414"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.ISRCTN82257414'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.ISRCTN82257414'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.ISRCTN82257414'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.ISRCTN82257414'


 

This table displays all metadata directly associated to this object as RDF triples.

78 TRIPLES      16 PREDICATES      70 URIs      62 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.ISRCTN82257414 schema:about anzsrc-for:3048
2 schema:description Background and study aims An ST segment Elevation Myocardial Infarction (STEMI) is a heart attack caused by a completely blocked blood vessel. Heart attacks are increasingly being treated by re-opening the blocked heart artery and placing a metal-mesh tube (stent). This is called primary percutaneous coronary intervention or PPCI. In addition to scaffolding the artery with a stent, drugs are used to thin the patient’s blood. We have recently changed the drugs given to patients presenting to the Bristol Heart Institute with heart attacks. The drugs we have selected are potent blood thinners and have been shown to act very fast. We will describe the relationship between blood thinning at the end of the procedure with the time given for the drug to take effect, and ultimately with side effects developed within the first 30 days after stenting. Who can participate? Patients aged 18 and over with an acute STEMI (heart attack) and undergoing PPCI. What does the study involve? The patients’ blood clotting ability is assessed on arrival at the hospital, at the completion of the PPCI, and at 1, 2 and 24 hours after the completion of the PPCI. This is a simple blood test, taking 3 ml of blood at each time, a total of 15 ml of blood. Following the procedure, patients are usually transferred to the coronary care unit (CCU), where they receive further drug treatment, undergo an echocardiogram (heart scan), and contact is made with the cardiac rehabilitation team. Ideally, patients transfer from the CCU to a cardiology ward after 24 hours and discharge is arranged from 48 hours onwards. All patients are invited to a clinic 1 month later. At this appointment any ongoing symptoms/problems are assessed, a 12-lead ECG is undertaken (recording the heart's electrical activity), and a clinical examination is performed, including weight, height, heart rate and blood pressure. Where necessary, the patients' medication is adjusted and further investigations are arranged for ongoing care. What are the possible benefits and risks of participating? This is an observational study so there are no benefits or risks of participating. Where is the study run from? Bristol Heart Institute at the Bristol Royal Infirmary (UK). When is the study starting and how long is it expected to run for? March 2011 to October 2012. Who is funding the study? The study is funded from Above and Beyond Project 353. Who is the main contact? Dr Thomas Johnson Tom.Johnson@UHBristol.nhs.uk
3 schema:endDate 2012-10-31T00:00:00Z
4 schema:keywords Appointment and Schedule
5 Institute
6 Johnson
7 Lead
8 Main
9 March
10 October
11 UK
12 artery
13 benefit
14 blood
15 blood pressure
16 blood thinner
17 blood vessel
18 cardiac rehabilitation
19 cardiology
20 clinic
21 clinical examination
22 completion
23 coronary care unit
24 discharge
25 drug
26 drug treatment
27 echocardiogram
28 electrical activity
29 heart
30 heart artery
31 heart attack
32 heart rate
33 height
34 hospital
35 medication
36 metal
37 method
38 myocardial infarction
39 observational study
40 ongoing care
41 onwards
42 patient
43 patient blood
44 percutaneous coronary intervention
45 platelet function
46 platelet inhibition
47 possible benefit
48 recording
49 risk
50 run
51 side effect
52 simple blood
53 stent
54 stenting
55 transfer
56 weight
57 schema:name A study of Platelet INhibition using a 'POINT of care' platelet function test, following Primary Percutaneous Coronary Intervention for ST elevation myocardial infarction (PINPOINT-PPCI)
58 schema:sameAs https://app.dimensions.ai/details/clinical_trial/ISRCTN82257414
59 schema:sdDatePublished 2019-03-07T15:20
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher N7d42750dbb294386bd1ca80a3d6f47c0
62 schema:sponsor https://www.grid.ac/institutes/grid.410421.2
63 https://www.grid.ac/institutes/grid.423000.5
64 schema:startDate 2011-03-17T00:00:00Z
65 schema:subjectOf sg:pub.10.1186/1471-2261-14-44
66 schema:url http://www.isrctn.com/ISRCTN82257414
67 sgo:license sg:explorer/license/
68 sgo:sdDataset clinical_trials
69 rdf:type schema:MedicalStudy
70 N7d42750dbb294386bd1ca80a3d6f47c0 schema:name Springer Nature - SN SciGraph project
71 rdf:type schema:Organization
72 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
73 rdf:type schema:DefinedTerm
74 sg:pub.10.1186/1471-2261-14-44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018754243
75 https://doi.org/10.1186/1471-2261-14-44
76 rdf:type schema:CreativeWork
77 https://www.grid.ac/institutes/grid.410421.2 schema:Organization
78 https://www.grid.ac/institutes/grid.423000.5 schema:Organization
 




Preview window. Press ESC to close (or click here)


...